Kardigan raises $400.0M IPO (United States, Jun 2026)

Kardigan extends biotech’s streak of big IPOs with $400M haul - BioPharma Dive

Kardigan is a cardiovascular drug startup focused on developing innovative treatments for heart conditions. The company has raised significant funding through both private venture capital and an initial public offering, highlighting its rapid growth and the increasing interest in biotech investments. Its lead drug, danicamtiv, is in late-stage testing for dilated cardiomyopathy, a condition currently lacking approved treatments.

Kardigan extends biotech’s streak of big IPOs with $400M haul  BioPharma Dive